Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Sanofi: EASIE Study Adds Valuable Data To Strengthen Lantus' Efficacy Profile

6/9/2012 8:37 AM ET

Sanofi (SNY: Quote) announced that people with early type 2 diabetes uncontrolled on metformin showed superior HbA1c - glycated hemoglobin - reduction with Lantus versus sitagliptin. The company reported presentation of these data from the EASIE study at the American Diabetes Association 72nd Scientific Sessions.

The company stated that about 50 percent more patients on Lantus achieved target HbA1c versus sitagliptin at study endpoint.

Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi, said, "The EASIE study adds valuable data to further strengthen the efficacy profile of Lantus when initiated early in the treatment pathway after metformin,"

Click here to receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After showing a lack of direction throughout much of the session, stocks ended Monday's trading modestly lower. The slightly lower close on the day partly offset the strength that was seen in the markets last week. The major averages ended the day below the unchanged line but off their lows for the session. President Barack Obama reportedly plans to deliver a much-anticipated speech on Thursday outlining his administration's evolving counterterrorism policies. Multiple news sources cited a White House official as saying that Obama will address the use of drones and plans to close the detention facility at Guantanamo Bay in a speech at the National Defense University. A second union representing immigration enforcement officers has expressed opposition to the Senate version of comprehensive immigration reform legislation, arguing that the bill fails to address the "insurmountable bureaucracy" at the agency that oversees lawful immigration to the U.S.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.